Sign In

Bob Linke

Chief Executive Officer at Osmol Therapeutics, Inc.

Bob Linke is a seasoned Pharma/biopharmaceutical CEO known for his exceptional ability in building and leading emerging companies through various growth phases.

Throughout his career, Bob has secured over $50 million in investor capital and $20 million in non-dilutive grant funding for company development while intricately developing robust patent portfolios to enhance company value.

With a profound understanding of customer needs, Bob excels in focusing organizations and fostering an open management style that cultivates a cohesive, high-performing team.

His extensive experience encompasses deep business insights and marketing/sales leadership within the multi-billion-dollar pharma industry, along with expertise in health informatics, device, and diagnostic markets.

Bob Linke holds an MBA in General Management from Harvard Business School and a BA in Economics and Mathematics from Albion College.

Throughout his career, Bob has held several significant leadership positions, including Chief Executive Officer at Osmol Therapeutics, Inc., Founder and President at RBL Life Science Advisors, LLC, and Executive Chairman of the Board of Directors at Embera NeuroTherapeutics, among others.

Highlights

Aug 21 · linkedin

Knowing that chemotherapy patients face daily choices that impact their quality of life is painful, deciding whether or not to proceed with their cancer treatment should not be one of those choices. As OSM-205 prepares to enter the clinic later this year, Osmol Therapeutics continues to confront/address/tackle this critical challenge in cancer care to help patients receive the best cancer treatment possible. https://bit.ly/4dw1EmE #biopharma #cancercare

Jul 19 · linkedin

I am thrilled to be driving Osmol Therapeutics's efforts in advancing OSM-0205, a revolutionary treatment for chemotherapy-induced peripheral neuropathy (CIPN), and preparing for clinical programming later this year.

By targeting CIPN with OSM-0205, we strive to allow patients to continue their treatment without disruption.

Watch our video for insights on its potential impact on patient lives.

Bob Linke
Add to my network

Location

United States